Liquid biopsy

A lab-on-a-chip device that can detect exosomes from tumors in the blood could revolutionize early cancer diagnosis.

The gold standard for monitoring acute myeloid leukemia relapse after bone marrow transplant is chimerism testing – but is it sensitive enough?

Liquid biopsy has shown promise as a rapid, minimally invasive way to profile tumors – but are commercially available tests accurate and consistent?

The use of saliva as a diagnostic fluid seems an attractive option – especially now that research reveals circulating tumor DNA in the fluid

To harness liquid biopsy’s many advantages, it’s vital to ensure appropriate testing – and cfDNA synthetic plasma reference standards can help

Markers such as DNA methylation, analyzed by liquid biopsy, may improve on ovarian cancer testing options like gold standard CA125

New biomarker sensing technology can detect miniscule concentrations of molecules in the blood to assist with patient monitoring

Epigenetics may combine with liquid biopsy to offer an effective way of detecting early-stage cancers and recurrences

When seeking the greatest benefit from liquid biopsy, droplet digital PCR can help by offering speed, sensitivity, and absolute quantitation

A combination of magnetic particles that bind circulating tumor cells and a magnetic wire that samples them directly from the vein could lead to earlier diagnosis